VCP‐Regulated LMF2 Stabilizes the Cholesterol Biosynthesis Enzyme HMGCS1 to Drive Cancer Progression and Confer Capecitabine Resistance in Triple‐Negative Breast Cancer
A previously unrecognized VCP‐LMF2‐HMGCS1 regulatory axis that drives TNBC progression and chemoresistance is unveiled, and lipase maturation factor 2 is identified as a promising therapeutic target for this recalcitrant disease.